Hematology News and Research

RSS

Hematology, also spelled haematology, is the branch of biology (physiology), pathology, clinical laboratory, internal medicine, and pediatrics that is concerned with the study of blood, the blood-forming organs, and blood diseases. Hematology includes the study of etiology, diagnosis, treatment, prognosis, and prevention of blood diseases.

IV iron dextran more cost-effective than oral iron for women with heavy menstrual bleeding and IDA

A single dose of intravenous (IV) iron dextran is the cost-effective treatment for women with heavy menstrual bleeding and iron deficiency anemia (IDA), according to new research published in Blood Advances.

8 Jan 2026

Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer

Triple-negative breast cancer (TNBC) is among the most aggressive types of breast cancer, lacking estrogen, progesterone, and HER2 receptors and thus relying primarily on cytotoxic chemotherapy.

7 Jan 2026

New method can help better assess precision genome editing technology

Scientists and physicians can better assess precision genome editing technology using a new method made public today by St. Jude Children's Research Hospital. Significant amounts of time and resources spent improving CRISPR gene editing technology focus on identifying small off-target sites that pose a safety risk, which is also technically challenging.

2 Jan 2026

Precision immunotherapy for TRBC2-positive T-cell malignancies

Researchers at the Johns Hopkins Kimmel Cancer Center's Ludwig Center developed a new treatment that selectively targets TRBC2-positive T-cell cancers, expanding a precision approach they established in 2024 for TRBC1-positive tumors.

22 Dec 2025

New AI model brings precision medicine to multiple myeloma care

C. Ola Landgren, M.D., Ph.D., received HealthTree Foundation's prestigious 2025 Innovation Award for his work in developing CORAL, a new research tool that leverages AI to predict individual outcomes and guide treatment decisions in patients with multiple myeloma.

19 Dec 2025

Advances in hemophilia gene therapy bring hope for pediatric patients

In the past three years, gene therapy has reshaped what's possible in hemophilia treatment for patients 18 and older. But a key question remains: How soon will these advances reach children?

18 Dec 2025

Novel mRNA therapy rejuvenates immune function in aging mice

Can the weakened immune systems of older individuals be rejuvenated? Researchers from the German Cancer Research Center (DKFZ), the HI-STEM institute, and the Broad Institute have demonstrated that this is possible with an innovative approach.

17 Dec 2025

New in vitro platform predicts drug toxicity, improving cancer treatment safety

Overcoming acquired treatment resistance is one of the major challenges in the fight against cancer. While combination therapies hold promise, their toxicity to healthy tissue remains a major hurdle. To anticipate these risks, researchers at the University of Geneva (UNIGE) have developed in vitro models of the kidneys, liver, and heart - three organs particularly sensitive to such therapies.

16 Dec 2025

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

12 Dec 2025

Immune checkpoint inhibitors can trigger rare immune thrombocytopenia in cancer patients

Researchers led by investigators at Mass General Brigham have published valuable information about a rare but serious complication of anti-cancer immunotherapy, providing the first large-scale description of its risk factors and clinical course, and underscoring the importance of early diagnosis and treatment.

12 Dec 2025

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Over the past few decades, advances in hematology have illuminated how a delicate balance between stem cell self-renewal and differentiation sustains healthy blood formation.

12 Dec 2025

Disrupted genome architecture drives lymphoma development

Cancer isn't just about broken genes-it's about broken architecture. Imagine a city where roads suddenly vanish, cutting off neighborhoods from essential services.

10 Dec 2025

Expanded donor matching makes stem cell transplants accessible

For years, the search for a stem cell donor has felt like a quest for a rare key-one that fits a lock with eight intricate tumblers, each representing a genetic marker.

10 Dec 2025

Antibody therapy clears residual multiple myeloma in early trial

Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine.

10 Dec 2025

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly improved recurrence risk stratification in hormone receptor (HR)-positive, HER2-negative breast cancer, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12, 2025.

10 Dec 2025

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Researchers from The University of Texas MD Anderson Cancer Center presented promising new data from two ongoing studies of pivekimab sunirine (PVEK), an antibody-drug conjugate targeting CD123, in treating two aggressive blood cancers at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

$Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma$

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Patients with relapsed or refractory (R/R) multiple myeloma who received a combination of teclistamab, a bispecific monoclonal antibody, and daratumumab, a CD38-directed monoclonal antibody, were 83% more likely to be alive without disease progression compared with those who received standard second-line therapies at a median of nearly 35 months of follow-up, according to the results of a new trial presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition.

10 Dec 2025

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

In a new trial, the Bruton tyrosine kinase (BTK) inhibitor pirtobrutinib increased the rate of survival without disease progression and was well tolerated with a more favorable safety profile when compared with bendamustine plus rituximab (BR) in patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

10 Dec 2025

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

A new national study shows for the first time that people exposed to Agent Orange face a higher risk of developing myelodysplastic syndrome (MDS), tend to develop it earlier, and often have more aggressive disease that is more likely to progress to acute myeloid leukemia.

9 Dec 2025

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

More than half of patients in a Phase III clinical trial who received a limited course of the experimental monoclonal antibody ianalumab for primary immune thrombocytopenia (ITP), an autoimmune disorder that can cause life-threatening bleeding, were able to maintain safe platelet counts without serious bleeding episodes for at least one year.

9 Dec 2025

Hematology News and Research

Further Reading

IV iron dextran more cost-effective than oral iron for women with heavy menstrual bleeding and IDA

Pitavastatin shows pomise in overcoming chemotherapy resistance in triple-negative breast cancer

New method can help better assess precision genome editing technology

Precision immunotherapy for TRBC2-positive T-cell malignancies

New AI model brings precision medicine to multiple myeloma care

Advances in hemophilia gene therapy bring hope for pediatric patients

Novel mRNA therapy rejuvenates immune function in aging mice

New in vitro platform predicts drug toxicity, improving cancer treatment safety

Combining inhibitors and chemotherapy enhances treatment for aggressive leukemia subtypes

Immune checkpoint inhibitors can trigger rare immune thrombocytopenia in cancer patients

Researchers identify chromatin accessibility changes driving stem cell transformation in MDS

Disrupted genome architecture drives lymphoma development

Expanded donor matching makes stem cell transplants accessible

Antibody therapy clears residual multiple myeloma in early trial

AI model improves recurrence risk stratification in HR-positive, HER2-negative breast cancer

Two ongoing studies show promise of pivekimab sunirine in treating aggressive blood cancers

Tec-Dara could represent a new standard of care for relapsed or refractory multiple myeloma

Pirtobrutinib shows superior outcomes compared to common first-line combination treatment for CLL/SLL

People exposed to Agent Orange face higher risk of developing myelodysplastic syndrome

Research ushers in a new era of hope for patients with primary immune thrombocytopenia

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo